The Antiobesity Effect of GLP-1 Receptor Agonists Alone or in Combination with Metformin in Overweight /Obese Women with Polycystic Ovary Syndrome: A Systematic Review and Meta-Analysis

Table 2

Characteristics of the studies included in the meta-analysis.

Study ID

Intervention

Control

Type (dose)

N

Age

BWB (kg)

WCB (cm)

BMIB (kg/m^2)

Type (dose)

N

Age

BWB (kg)

WCB (cm)

BMIB (kg/m^2)

(BWC)

(WCC)

(BMIC)

(BWC)

(WCC)

(BMIC)

1

EXE (10 μg BID)

14

28.2 ± 4.9

110.5 ± 26.8 (−3.2 ± 0.4)

40.3 ± 8.9 (−1.0 ± 1.1)

MET (1000 mg BID)

7

27.7 ± 5.8

113.4 ± 31.3 (−1.6 ± 0.8)

43.3 ± 8.9 (−1.0 ± 1.1)

2

EXE (10 μg BID) + MET (1000 mg BID)

14

32.1 ± 3.1

112.0 ± 35.8 (−6.0 ± 1.9)

40.9 ± 8.9 (−1.7 ± 1.1)

MET (1000 mg BID)

7

27.7 ± 5.8

113.4 ± 31.3 (−1.6 ± 0.8)

43.3 ± 8.9 (−1.0 ± 1.1)

3

LIRA (1.2 mg QD)

11

31.5 ± 6.4

108.9 ± 15.1 (−3.8 ± 3.7)

124.9 ± 9.9 (−3.2 ± 2.9)

39.3 ± 4.2 (−1.3 ± 1.3)

MET (1000 mg BID)

7

31.3 ± 9.4

103.2 ± 6.3 (−1.2 ± 1.4)

122.3 ± 7.0 (−1.6 ± 2.9)

36.6 ± 3.5 (−0.5 ± 0.5)

4

LIRA (1.2 mg QD) + MET (1000 mg BID)

11

31.1 ± 5.1

105.5 ± 20.6 (−6.5 ± 2.8)

121.9 ± 17.7 (−5.5 ± 3.8)

37.6 ± 5.1 (−2.4 ± 1.0)

MET (1000 mg BID)

7

31.3 ± 9.4

103.2 ± 6.3 (−1.2 ± 1.4)

122.3 ± 7.0 (−1.6 ± 2.9)

36.6 ± 3.5 (−0.5 ± 0.5)

5

LIRA (1.2 mg QD)

14

29.5 ± 7.7

113.7 ± 18.7 (−3.0 ± 3.4)

128.5 ± 13.9 (−4.4 ± 5.0)

41.6 ± 5.3 (−1.1 ± 1.1)

MET (1000 mg BID)

14

25.3 ± 5.2

103.6 ± 19.7 (−2.3 ± 2.6)

121.6 ± 17.1 (−2.6 ± 3.0)

37.4 ± 6.4 (−0.9 ± 0.9)

6

LIRA (1.2 mg QD)

14

30.7 ± 7.9

102.8 ± 16.3 (−3.1 ± 3.5)

115.7 ± 12.5 (−3.1 ± 2.8)

36.7 ± 5.6 (−1.1 ± 1.3)

MET (1000 mg BID)

13

30.7 ± 7.9

108.3 ± 17.0 (−0.2 ± 1.8)

120.5 ± 14.5 (0.8 ± 1.9)

39.4 ± 6.9 (−0.1 ± 0.7)

7

EXE (10 μg BID)

80

27.9 ± 2.7

73.0 ± 9.8 (−4.3 ± 1.3)

93.0 ± 10.1 (−9.0 ± 3.8)

29.2 ± 3.1 (−3.1 ± 1.4)

MET (1000 mg BID)

78

27.7 ± 3.8

70.4 ± 4.6 (−2.3 ± 0.6)

89.4 ± 6.6 (−5.0 ± 4.7)

28.3 ± 1.9 (−1.0 ± 0.2)

8

LIRA (1.2 mg QD) + MET (1000 mg BID)

14

30.1 ± 3.6

106.6 ± 11.7 (−7.5 ± 3.9)

114.5 ± 9.9 (−11.7 ± 9.0)

37.8 ± 3.0 (−2.7 ± 1.3)

MET (1000 mg BID)

14

31.1 ± 4.7

99.6 ± 17.8 (−7.0 ± 6.0)

108.8 ± 14.5 (−11.3 ± 9.2)

35.5 ± 4.9 (−2.5 ± 2.0)

BID: twice daily; QD: once daily; BWB: body weight baseline (kg); BWC: body weight changes (kg); WCB: waist circumference baseline (cm); WCC: waist circumference changes (cm); BMIB: body mass index baseline (kg/m²); BMIC: body mass index changes (kg/m²); EXE: exenatide; LIRA: liraglutide; MET: metformin.